Karyopharm Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Good morning. I'm Eric Joseph, one of the senior biotech analysts at JPMorgan. And our next presenting company is Karyopharm Pharmaceuticals -- or Karyopharm Therapeutics, rather. It's my pleasure to welcome CEO, Michael Kauffman, to tell us a little bit about the company. Just as a reminder, the Q&A breakout session will be held in the Sussex Room. With that, Michael?
Thanks, Eric, and welcome, everybody today. It's great to be here. It's been a heck of a year for us and dive right in. As you all know, I'll make forward-looking statements. Please do review this slide and all the information in it. Now you're done reviewing. .
Karyopharm's vision is to become a leading oncology company. We are the first company that has received approval for an oral Exportin 1 inhibitor, XPOVIO, and we have a few direct competitors in development. XPOVIO, U.S. accelerated approval occurred on
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |